CENTER FOR DRUG EVALUATION AND RESEARCH

Application Number 21-003
21-004

CHEMISTRY REVIEW(S)

DIVISION OF ANTIVIRAL DRUG PRODUCTS
Review of Chemistry, Manufacturing and Controls

NDA #: 21,003

CHEMISTRY REVIEW #: 1 **DATE REVIEWED:** 4-Jun-98

SUBMISSION TYPE	DOCUMENT DATE	CDER DATE	ASSIGNED DATE
Original	29-Apr-98	30-Apr-98	14-May-98
Amendment	12-Jun-98	15-Jun-98	15-Jun-98
Amendment	24-Jun-98	24-Jun-98	29-Jun-98
Amendment	30-Jul-98	31-Jul-98	5-Aug-98
Amendment	17-Nov-98	17-Nov-98	17-Nov-98

NAME / ADDRESS OF APPLICANT: Glaxo Wellcome Inc.
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709

DRUG PRODUCT NAME

Proprietary: EPIVIR®-HBV™ Tablets
Nonproprietary: lamivudine tablets
Code Name/#:

PHARMACOLOGICAL CATEGORY: Antiviral
INDICATION: Anti-hepatitis B
DOSAGE FORM/STRENGTH: Film-coated tablets, 100 mg
ROUTE OF ADMINISTRATION: Oral

CHEMICAL NAME / STRUCTURAL FORMULA:

(2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one



Registry Number [134678-17-4]

$C_8H_{11}N_3O_3S$ Formula Weight: 229.26

CONCLUSIONS & RECOMMENDATIONS:

The NDA submission and accompanying amendments provide adequate information on the chemistry, manufacturing and controls for EPIVIR®-HBV™ (lamivudine) Tablets and the manufacturing facilities have acceptable cGMP status. The NDA, as amended, is therefore recommended for approval from the chemistry perspective.

/S/ 12/30/98
George Lunn, Ph.D.
Review Chemist

Concurrence:
HFD-530/SMiller /S/

cc:
Orig. NDA 21,003
HFD-530/Div. File
HFD-530/GLunn
HFD-530/SMiller
HFD-530/AZeccola
HFD-530/BStyrt
HFD-530/PVerma
HFD-530/NBattula
HFD-530/Biopharm
HFD-530/PFlyer
HFD-830/CChen

APPEARS THIS WAY
ON ORIGINAL

DIVISION OF ANTIVIRAL DRUG PRODUCTS
Review of Chemistry, Manufacturing and Controls

NDA #: 21,004

CHEMISTRY REVIEW #: 1 **DATE REVIEWED:** 10-Aug-98

SUBMISSION TYPE	DOCUMENT DATE	CDER DATE	ASSIGNED DATE
Original	29-Jun-98	30-Jun-98	7-Aug-98
Amendment	17-Nov-98	17-Nov-98	17-Nov-98
Amendment	23-Nov-98	23-Nov-98	23-Nov-98

NAME / ADDRESS OF APPLICANT: Glaxo Wellcome Inc.
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709

DRUG PRODUCT NAME
Proprietary: EPIVIR®-HBV™ Oral Solution
Nonproprietary: lamivudine oral solution
Code Name/#:

PHARMACOLOGICAL CATEGORY: Antiviral
INDICATION: Anti-hepatitis B
DOSAGE FORM/STRENGTH: Oral solution, 5 mg/mL
ROUTE OF ADMINISTRATION: Oral

CHEMICAL NAME / STRUCTURAL FORMULA:

(2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one





$C_8H_{11}N_3O_3S$ Formula Weight: 229.26

CONCLUSIONS & RECOMMENDATIONS:

The NDA submission and accompanying amendments provide adequate information on the chemistry, manufacturing and controls for EPIVIR®-HBV™ (lamivudine) Oral Solution and the manufacturing facilities have acceptable cGMP status. The NDA, as amended, is therefore recommended for **approval** from the chemistry perspective.

/S/ 1/30/98

George Lunn, Ph.D.
Review Chemist

Concurrence:
HFD-530/Smiller /S/

cc:
Orig. NDA 21.004
HFD-530/Div. File
HFD-530/GLunn
HFD-530/SMiller

HFD-530/AZeccola
HFD-530/BStyrt
HFD-530/PVerma
HFD-530/NBattula
HFD-530/Biopharm
HFD-530/PFlyer
HFD-830/CChen